Clinical Trial Update: DOTATOC PET/CT for Imaging NET Patients

View source ↗

Summary

ClinicalTrials.gov entry describes a DOTATOC PET/CT imaging study for neuroendocrine tumors, sponsored by the British Columbia Cancer Agency, with the status cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrinoma
• Insulinoma
• Medullary Thyroid Carcinoma
• Merkel Cell Carcinoma
• Neuroendocrine Tumor
• Paraganglioma
• Pheochromocytoma
• Small Cell Lung Carcinoma

Drugs mentioned

• DOTATOC (DOTA-D-Phe1-Tyr3-Octreotate)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Neuroendocrine Tumors, Insulinoma | Status: ACTIVE_NOT_RECRUITING